InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder_老虎社区_美港股上老虎

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

seekingalpha2022-07-06

Grandbrothers The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

道琼斯工业平均指数
·2022-07-07
👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8@123是是是*；
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2249517541?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-07-06 19:47","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2249517541","market":"us","top_or_hot":-1,"title":"InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder","media":"seekingalpha","content":"<div>\n<p>Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).\nPG is a rare disorder ...</p>\n\n<a href=\"https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-06 19:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).\nPG is a rare disorder ...</p>\n\n<a href=\"https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status","article_id":"2249517541","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2249517541","pubTimestamp":1657108048,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaR","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4581":"高盛持仓","PG":"宝洁","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4504":"桥水持仓","IFRX":"InflaRx N.V.","BK4558":"双十一","BK4567":"ESG概念","BK4018":"居家用品","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓"},"translate_title":"随着vilobelimab获得FDA皮肤病快速通道地位，InflaRx股价上涨14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":1,"PG":1},"content_text":"Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).\nPG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs.\nThe company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release.\nVilobelimab has already received orphan drug status for PG in the U.S. and EU.\nIFRX +14.08% to $1.62 premarket July 6","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":681795406,"gmtCreate":1657162575609,"gmtModify":1704866721465,"author":{"id":"3551449686726984","authorId":"3551449686726984","name":"道琼斯工业平均指数","avatar":"https://static.tigerbbs.com/918d9a8a8166958e94c7f6e8ccc65d70","vip":1,"hat":"https://static.tigerbbs.com/e6295840391b9cdc17115677ba51429c","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3551449686726984","idStr":"3551449686726984"},"htmlText":"👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8<a href=\"https://laohu8.com/U/3573704321965451\">@123是是是</a>*；","listText":"👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8<a href=\"https://laohu8.com/U/3573704321965451\">@123是是是</a>*；","text":"👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8@123是是是*；","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/681795406","repostId":2249517541,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}